Type 2 diabetes and metabolic syndrome as conditions leading to malignant tumors;A metabolikus szindróma és a 2-es típusú diabetes mellitus mint rosszindulatú daganatra hajlamosító állapotok

Orvosi Hetilap

Volumn 149, Issue 51, 2008, Pages 2403-2411

  Halmos, Tamás ^a,c   Suba, Ilona ^b  

^a Mazsihisz Szeretet Kórház Metabolikus Ambulancia   (Hungary)

^b Bajcsy Zsilinszky District Hospital   (Hungary)

^c NONE   (Hungary)

Author keywords

Cancer; Common developmental pathways; Metabolic syndrome; Type 2 diabetes

Indexed keywords

ADIPONECTIN; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; CYTOKINE; GLUCOSE; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 3; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; LEPTIN; MACROPHAGE INFLAMMATORY PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PROINSULIN; PROTEASOME; REACTIVE OXYGEN METABOLITE; SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UBIQUITIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

ADIPOSE TISSUE; ANGIOGENESIS; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CANCER RISK; CARCINOGENESIS; CAUSAL ATTRIBUTION; CELL PROLIFERATION; CYTOKINE RELEASE; ETHNICITY; GENDER; GEOGRAPHY; GLUCOSE TRANSPORT; HUMAN; HYPERGLYCEMIA; HYPERINSULINISM; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; METABOLIC SYNDROME X; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOPHYSIOLOGY; RISK FACTOR; WAIST HIP RATIO;

EID: 58349099006     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: 10.1556/OH.2008.28507     Document Type: Article

References (50)

1. Masur K., Thévenod, F., Zänker, K. S. (szerk.): Diabetes and cancer. Epidemiological Evidence and Molecular Links. Karger, Basel, 2008.
2. Goodwin, P. J., Ennis, M., Pritchard, K. I és mtsai: Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J. Clin. Oncol., 2002, 20, 42-51.
3. Bloomgarden, Z.: Third annual world congress on the insulin resistance syndrome. Diabet. Care, 2006, 29, 2165-2174.
4. Cowey, S., Hardy, R. W.: The metabolic syndrome A: High-risk state for cancer? Am. J. Pathol., 2006, 169, 1505-1522.
5. Reaven, G. M.: The role of insulin resistance in human disease. Diabetes, 1988, 37, 1595-1607.
6. Eriksson, J., Taimela, S., Koivisto, V.A.: Exercise and the metabolic syndrome. Diabetologia, 1997, 40, 125-135.
7. Halmos T., Kautzky L., Suba I.: Metabolicus syndroma. Medicina Könyvkiadó Rt., Budapest, 2005.
8. Vermeulen L., Sprick, M. R., Kemper, K. és mtsai: Cancer stem cells - old concepts, new insights. Cell Death Differ., 2008, 15, 947-958, (Epub 2008 Feb 15)
9. DeBerardinis, R. J., Lum, J. J., Hatzivassiliou, G. és mtsa: The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell. Metab., 2008, 7, 11-20.
10. Gillies, R. J., Gatenhy, R. A.: Hypoxia and adaptive landscapes in the evolution of carcinogenesis. Cancer Metastasis Rev., 2007, 26, 311-317.
11. Ito, S., Futusato, T., Nemoto, T. és mtsai: Expression of glucose transporter-1 and matrix metalloproteinase-2 in human cancer. J. Natl. Cancer Inst., 2002, 94, 1080-1091.
12. Macheda, M. L., Rogers, S., Best, J. D.: Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J. Cell. Physiol., 2005, 202, 654-662.
13. Stattin, P., Björ, O., Ferrari, P. és mtsai: Prospective study of hyperglycemia and cancer risk. Diabet. Care, 2007, 30, 561-567.
14. Jee, S. H., Ohrr, H, Sull, J. W. és mtsai: Fasting serum glucose level and cancer risk in Korean men and women. JAMA, 2005, 293, 194-202.
15. Kuriki, K., Hirose, K., Tajima, K.: Cancer risk for all and specific sites among Japanese men and women. Eur. J. Cancer. Prev., 2007, 16, 87-89.
16. Stürmer, T., Buring, J. E., Lee, I. M. és mtsai: Metabolic abnormalities and risk for colorectal cancer in the physician's health study. Cancer Epidemiol. Biomarkers Prev., 2006, 15, 2391-2397.
17. Calle, E. E., Rodriguez, C., Walker-Thurmond, K. és mtsa: Owerweight, obesity and mortality from cancer in a prospectively studied cohort of U.S. adults. N. Engl. J. Med., 2003, 348, 1625-1638.
18. Suba, Zs., Barabás, J., Szabó, Gy. és mtsa: Increased prevalence of diabetes and obesity in patients with salivary gland tumors. Diabet. Care, 2005, 28, 228-230.
19. Dombrowski, F., Klotz, L., Bannasch és mtsa: Renal carcinogenesis in models of diabetes in rats - metabolic changes are closely related to neoplastic development. Diabetologia, 2007, 50, 2580-2590.
20. Moore, L. E., Wilson, R. T., Campleman, S. L.: Lifestyle factors, exposures, genetic susceptibility, and renal cell cancer risk: a review. Cancer Invest., 2005, 23, 240-255.
21. Jing, M. A., Giovanucci, E., Pollak, M. és mtsa: A prospective study of plasma C-pepticle and colorectal cancer risk in men. J. Natl. Cancer Inst., 2004, 96, 546-553.
22. Morita, T.: The metabolic syndrome is associated with increased risk of colorectal adenorna development: the Self-Defence Forces Health Study. Asian Pacific J. Cancer Prev., 2005, 6, 485-489.
23. Beebe-Dimmer, J. L., Dunn, R. L., Sarma, A. V. és mtsai: Features of the metabolic syndrome and prostate cancer in African-American men. Cancer, 2007, 109, 875-881.
24. Vona -Davis, L., Howard, M. C., Natt, M. és mtsai: Adiposity, type 2 diabetes and the metabolic syndrome in breast cancer. Obes. Rev., 2007, 8, 395-408.
25. Meyerbardt, J. A., Sloan, J. A., Sargent, D. J. és mtsai: Association between plasma insulin-like growth factor proteins and C-peptide and quality of life in patients with metastatic colorectal cancer. Cancer Epidemiol. Biomarkers Prev., 2005, 14, 1402-1410.
26. Fuji, T., Ishikawa, T., Kanazumi, N. és mtsai: Analyses of clinico-pathological features and predictors of malignancy in intraductal papillary mucinous neoplasms (IPMN-s) are increasing. Hepatogastroenterology, 2007, 54, 272-277.
27. Bugianesi, E.: Non-alcoholic steatohepatitis and cancer. Clin. Liver Dis., 2007, 11, 191-207.
28. Kershaw, E. E., Flier, J. S.: Adipose tissue as an endocrine organ. J. Clin. Endocrinol. Metab., 2004, 89, 2548-2556.
29. Key, T. J., Appleby, P. N., Reeves, G. K. és mtsai: Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J. Natl. Cancer Inst., 2003, 95, 1218-1226.
30. Kaaks, R., Lukanova, A., Kurzer M. S.: Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomarkers Prev., 2002, 11, 1531-1543.
31. Hagymási, K., Tulassay, Zs.: Az elhízás szerepe a vastagbéldaganatok kialakulásában. Orv. Hetil., 2007, 148, 2411-2415.
32. Abe, R., Yamagishi, S.: AGE-RAGE system and carcinogcnesis. Curr. Pharm. Des., 2008, 14, 940-945.
33. Larsson, S. C., Berqkvist, L., Wolk, A.: Consumption of sugar and sugar sweetened foods and the risk of pancreatic cancer in a prospective study. Am. J. Clin. Nutr., 2006, 94, 1293-1300.
34. Macheda, M. L., Rogers, S., Best, J. D.: Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J. Cell. Physiol., 2005, 202, 654-662.
35. Hausman, G. J., Richardson, R. L.: Adipose tissue angiogenesis. J. Anim. Sci., 2004, 82, 925-934.
36. Moscbos, S. J., Mantzoros, C. S.: The role of the IGF system in cancer: from basic to clinical studies and clinical applications. Oncology, 2002, 63, 317-332.
37. Muntoni, S., Muntoni, S., Draznin, B.: Effects of chronic hyperinsulinemia in insulin resistant patients. Curr. Diab. Rep., 2008, 8, 233-238.
38. Harish, K.: Study protocol: Insulin and it's role in cancer. BMC Endocr. Disord., 2007, 7, 10.
39. Calle, E. E., Kaaks, R.: Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat. Rev. Cancer, 2004, 4, 579-591.
40. Ibrahim, Y. H., Yee, D.: Insulin-like growth factor-I and cancer risk. Growth Horm IGF Res., 2004, 14, 261-269.
41. Halmos T., Suba I.: Extrapancreaticus hypoglykaemizáló tumorok. Orvosképzés, 1977, 52, 233-240.
42. Valko, M., Izakovic, M., Mazur, M. és mtsai: Role of oxygen radicals in DNA damage and cancer incidence. Mol. Cell. Biochem., 2004, 266, 37-56.
43. Hausman, G. J., Richardson, R. L.: Adipose tissue angiogenesis. J. Anim. Sci., 2004, 82, 925-934.
44. Miyazawa-Hoshimoto, S., Takahashi, K., Bujo, H. és mtsai: Elevated serum vascular endothelial growth factor is associated with visceral fat accumulation in human obese subjects. Diabetologia, 2003, 46, 148 3-1488.
45. Fantuzzi, G.: Adipose tissue, adipokines, and inflammation. J. Allergy Clin. Immunol., 2005, 115, 911-919.
46. Sonnenberg, G. E., Krakower G. R., Kissebah, A. H.: A novel pathway to the manifestations of metabolic syndrome. Obes. Res., 2004, 12, 180-186.
47. Ross, J. S., Stagliano, N. E., Donovan, M. J. és mtsai: Atherosclerosis and cancer: common molecular pathways of disease development and progression. Ann. NY. Acad Sci., 2001, 947, 271-292.; discussion: 292-293.
48. Girroir, E. E., Hollingshead, H. E., Billin, A. N. és mtsai: Peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) ligands inhibit growth of UACC903 and MCF7 human cancer cell lines. Toxicology, 2008, 243, 236-243.
49. Voutsadakis, I. A.: The ubiquitin-proteasome system in colorectal cancer. Biochim. Biophys. Acta, 2008, jún. 19. (Epub ahead of print)
50. Genini, D., Carbone, G. M., Catapano, C. V.: Multiple interactions between peroxisome proliferators-activated receptors and the ubiquitin-proteasome system and implications for cancer pathogenesis. PPAR Res., 2008, 195065.